Favipiravir for treating COVID-19: benefits and harms are uncertain (search done on 27 March 2020)

Added July 24, 2020

Citation: Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir–a potential treatment in the COVID-19 pandemic? Journal of Virus Eradication. 2020 Apr 30;6(2):45-51.

What is this? Favipiravir have been suggested as a possible treatment for COVID-19.

In this rapid review, the authors searched for studies on the safety of favipiravir in the treatment of COVID-19. They did not restrict their searches by type or language of publication and did their search on 27 March 2020. They included 6 phase 2 and 3 studies that provided safety data for a comparison of the number of adverse events in favipiravir and control groups (4299 participants with 175 person-years-of-follow-up).

What was found: At the time of this review, the included studies showed that although a favourable safety profile was reported in some patients who received favipiravir, its effectiveness for treating COVID-19 patients was uncertain.

 

Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.

Share